SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending following a proposed flat rate for Medicare Advantage payments in 2027 by the Trump administration, dramatically below industry expectations. This news, surfacing just before its earnings report, triggered a significant sell-off across the healthcare sector, with the community divided between panicked investors and those eyeing the dip as a prime buying opportunity. Many anticipate future negotiations or a rebound, viewing the sharp drop as an overreaction or market manipulation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is captivating the market after silver reached historic price levels, sparking a heated debate among traders about its sustainability. While some bulls anticipate continued parabolic gains driven by industrial demand and geopolitical factors, a significant bearish contingent warns of an imminent pullback, pointing to extreme volatility and potential market manipulation.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a trending topic, propelled by an exclusive AI licensing partnership for its Engagement Language Model in Africa, fueling immense community excitement. Traders are actively discussing the potential for a significant short squeeze, pushing for triple-digit price targets amidst warnings from bears about its rapid ascent.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending due to proposed flat Medicare Advantage payment rates for 2027 by CMS, which are significantly below analyst expectations and signal potential margin pressure for MA-heavy insurers. This news has sparked a sector-wide re-evaluation and a notable sell-off, despite recent reaffirmations of guidance and improved star ratings for some of its plans. The community is actively debating whether this is an overblown reaction, similar to past regulatory shocks, or if it indicates a more sustained challenge to profitability.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is actively trending as the community eagerly anticipates a significant NASA Lunar Terrain Vehicle (LTV) contract award, positioning the company as a leading contender in the burgeoning lunar economy. Investors are closely watching for this pivotal announcement, alongside the company's crucial role in communications and data tracking for the upcoming Artemis II mission, fueling speculation about its future trajectory within the space sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending following a significant $1.6 billion U.S. government investment through the CHIPS Program, coupled with a $1.5 billion private placement, aimed at securing a domestic rare earth supply chain. The community is actively discussing this strategic backing as a catalyst for substantial long-term growth and reduced reliance on foreign sources, drawing comparisons to past government-supported entities. Despite an initial price surge followed by a notable pullback, discussions persist about the long-term potential, short covering, and strategic importance of rare earth minerals for national security, though some voice concerns about valuation and 'pump' dynamics.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is attracting significant attention due to its expanding pipeline with acquired anticoagulant assets and ongoing advancements for its lead candidate, Tecarfarin, which holds FDA Fast Track and Orphan Drug designations. The community is sharply divided, with strong enthusiasm for its potential to modernize anticoagulation contrasting with skepticism around cash runway, dilution concerns, and allegations of promotional bot activity.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

The immediate catalyst driving conversations around CVS Health is the proposed essentially flat Medicare Advantage payment rates for 2027 by CMS, significantly below market expectations. This development is broadly perceived as a policy-driven margin squeeze risk for the healthcare sector, with the community actively discussing potential prolonged multiple compression and de-risking across MA-heavy insurers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending after Nvidia announced a $2 billion investment to accelerate the buildout of its AI data centers, which many interpret as a strong validation of its critical role in the AI infrastructure revolution. While some view this deepened partnership as a significant bullish catalyst, others remain skeptical, citing the discounted share purchase as a potential bailout for the unprofitable and highly indebted company. The community is actively debating whether this capital infusion strengthens CoreWeave's long-term stability or is a stopgap measure.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

Cel-Sci is drawing significant attention after its CEO made a substantial share purchase, which the community interprets as a strong signal of confidence. Investors are actively debating the potential approval of Multikine for Breakthrough Medicine Designation by the Saudi SFDA, a decision closely watched for its market entry implications amidst ongoing discussions about the drug's clinical trial history and broader financial strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Biotech Stocks To Keep An Eye On - December 9th

WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

<ul class="summary-bullets"><li>Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection.</li><li>Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection outcomes.</li><li>The treatment was well tolerated, with no burixafor-related side effects above Grade 2 reported in the study.</li></ul>Shares of Exicure Inc. (XCUR) surged nearly 40% on Tuesday after the company reported encouraging Phase 2 results for its experimental stem cell mobilization drug burixafor (GPC-100).&nbsp;The findings, shared at the American Society of Hematology meeting in Orlando, focused on patients with multiple myeloma preparing for autologous stem cell transplant.<h2 class="st-heading-2">Trial Meets Primary Endpoint</h2>The open-label, multicenter study found that 17 of 19 patients reached the trial’s stem cell collection target within two sessions. Two additional patients reached the target after an extra session.Among participants who proceeded to transplant, median neutrophil engraftment occurred in 13 days and platelet engraftment in 17.5 days. Exicure said burixafor worked quickly, boosting CD34+ stem cells, the cells doctors need to collect for transplant, within about an hour. The company said that the rapid rise makes it possible to give the drug and collect the cells on the same day.<h2 class="st-heading-2">Activity In Daratumumab-Exposed Patients</h2>Sixteen of 19 patients had previously received daratumumab, a therapy linked to reduced stem cell yield. Of these, 14 patients met the primary endpoint, including 12 of 14 who had also been treated with lenalidomide.Longer intervals between the last daratumumab dose and leukapheresis were associated with higher CD34+ cell yields.<h2 class="st-heading-2">Safety Findings</h2>The regimen of burixafor, propranolol, and G-CSF was well tolerated, with no adverse events above Grade 2 attributed to burixafor.“In this Phase 2 study, the combination of burixafor, G-CSF and propranolol showed an excellent safety profile and supported reliable mobilization of hematopoietic progenitor cells,” said lead investigator Jack Khouri of the Cleveland Clinic, adding that rapid cell mobilization may reduce the burden of the process for patients.<h2 class="st-heading-2">Pipeline Expansion Plans</h2>Burixafor, a selective CXCR4 antagonist acquired through Exicure’s January purchase of GPCR Therapeutics’ assets, is also being evaluated in sickle cell disease, rare transplant-eligible disorders, and cell and gene therapy settings.Exicure said a chemosensitization study in acute myeloid leukemia is planned, based on the drug’s ability to mobilize malignant cells from the bone marrow into peripheral blood.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Exicure was ‘extremely bullish’ amid ‘extremely high’ message volume. One user said, “Wow! This candle is showing a strong bullish setup. A powerful pump is coming.”<stembedurl>https://stocktwits.com/OmidArefi/message/638609203</stembedurl><figure class="image"><img style="aspect-ratio:968/141;" src="https://news.stocktwits-cdn.com/xcur_ss_png_95a0e0eba0.webp" alt="xcur ss.png" width="968" height="141"><figcaption>XCUR sentiment and message volume as of December 9| Source: Stocktwits</figcaption></figure>Another user called the stock cheap at the current price, “considering the data!”<stembedurl>https://stocktwits.com/Notoriousinvestor/message/638601332</stembedurl><a href="https://stocktwits.com/symbol/XCUR">Exicure’s stock</a> has declined 45% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exicure’s stock (XCUR) has declined 45% so far in 2025. (Photo credit: Getty Images)

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

Equity

Exicure, Inc. Loss At -$2.44 Mln In Q3

(RTTNews) - Exicure, Inc. (XCUR) reported Loss for third quarter of -$2.44 million...

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XCUR News

XCURExicure Inc